Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Royalty Pharma plc
  6. Summary
    RPRX   GB00BMVP7Y09

ROYALTY PHARMA PLC

(RPRX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/16/2021 09/17/2021 09/20/2021 09/21/2021 09/22/2021 Date
38.38(c) 38.5(c) 36.83(c) 36.63(c) 36.29(c) Last
3 146 018 17 928 292 3 670 263 1 692 984 1 290 536 Volume
+1.08% +0.31% -4.34% -0.54% -0.93% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 2 152 M - -
Net income 2021 1 315 M - -
Net Debt 2021 4 577 M - -
P/E ratio 2021 13,1x
Yield 2021 1,90%
Sales 2022 2 232 M - -
Net income 2022 1 493 M - -
Net Debt 2022 5 452 M - -
P/E ratio 2022 12,9x
Yield 2022 2,08%
Capitalization 15 496 M 15 496 M -
EV / Sales 2021 9,33x
EV / Sales 2022 9,39x
Nbr of Employees -
Free-Float 45,3%
More Financials
Company
Royalty Pharma plc is engaged in investing in late stage biopharmaceutical products. The Company invests in academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. The CompanyÔÇÖs portfolio of pharmaceutical investment includes investments in commercial products and development-stage product candidates. Its portfolio... 
Sector
Pharmaceuticals
Calendar
11/17Earnings Release
More about the company
Ratings of Royalty Pharma plc
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C-
More Ratings
All news about ROYALTY PHARMA PLC
09/06ROYALTY PHARMA : To present at upcoming investor conferences
AQ
09/03ROYALTY PHARMA : to Present at Upcoming Investor Conferences
AQ
08/25ROYALTY PHARMA : UBS Adjusts Royalty Pharma PT to $48 From $52, Maintains Buy Rating
MT
08/16ROYALTY PHARMA : Morgan Stanley Adjusts Price Target on Royalty Pharma to $46 From $51, Ma..
MT
08/11SECTOR UPDATE : Health Care Stocks Mixed Premarket Wednesday
MT
08/11ROYALTY PHARMA : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS O..
AQ
08/11ROYALTY PHARMA : Q2 Income Steady, Higher Revenue Beats Estimates; Shares Rise
MT
08/11ROYALTY PHARMA : Q2 Earnings Snapshot
AQ
08/11ROYALTY PHARMA PLC : Results of Operations and Financial Condition, Financial Statements a..
AQ
08/11ROYALTY PHARMA : Earnings Flash (RPRX) RP MANAGEMENT LLC Posts Q2 Revenue $555M, vs. Stree..
MT
08/11ROYALTY PHARMA : Reports Second Quarter 2021 Results
AQ
08/11Royalty Pharma plc Reports Unaudited Consolidated Financial Results for the Second Quar..
CI
08/11NORTH AMERICAN MORNING BRIEFING : Investors Await -2-
DJ
07/30ROYALTY PHARMA : Tigress Financial Initiates Coverage of Royalty Pharma with Buy Rating, $..
MT
07/28PRESS RELEASE : MorphoSys AG Reports Second -2-
DJ
More news
News in other languages on ROYALTY PHARMA PLC
07/29Morphosys macht mehr Umsatz - Operativer Verlust höher
07/28DGAP-NEWS : MorphoSys AG berichtet über die -2-
07/26Morphosys aktualisiert die Finanzprognose für 2021
07/26DGAP-ADHOC : Ad-hoc: MorphoSys AG aktualisiert die Finanzprognose für 2021 und reduziert F..
07/19DPA-AFX-ÜBERBLICK : UNTERNEHMEN vom 19.07.2021 - 15.15 Uhr
More news
Analyst Recommendations on ROYALTY PHARMA PLC
More recommendations
Chart ROYALTY PHARMA PLC
Duration : Period :
Royalty Pharma plc Technical Analysis Chart | RPRX | GB00BMVP7Y09 | MarketScreener
Technical analysis trends ROYALTY PHARMA PLC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 36,29 $
Average target price 51,43 $
Spread / Average Target 41,7%
EPS Revisions
Managers and Directors
Pablo Gerardo Legorreta Chairman & Chief Executive Officer
Terrance Patrick Coyne Chief Financial Officer & Executive Vice President
James F. Reddoch Chief Scientific Officer
George Lloyd Executive VP-Investments & General Counsel
Errol B. de Souza Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ROYALTY PHARMA PLC-27.49%15 496
JOHNSON & JOHNSON4.16%431 543
ROCHE HOLDING AG10.05%322 644
PFIZER, INC.19.32%246 414
NOVO NORDISK A/S50.62%232 291
ELI LILLY AND COMPANY35.22%206 972